The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2023 | Moving CAR-T therapy to earlier lines in multiple myeloma and clinical trials in this space
In this video, Hermann Einsele, MD, FRCP, University Hospital of Würzburg, Würzburg, Germany, discusses the benefits of moving CAR-T therapy to earlier lines of treatment in multiple myeloma, and further highlights clinical trials exploring this, including CARTITUDE-2 (NCT04133636), KarMMa-2 (NCT03601078), and CARTITUDE-6 (NCT05257083). This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
